Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Hydroxypropylmethylcellulose 0.3% and Sodium Hyaluronate 0.18% for Ocular Surface Disease in Glaucoma

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2011 by Mahidol University.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Mahidol University
ClinicalTrials.gov Identifier:
NCT01284439
First received: January 25, 2011
Last updated: January 26, 2011
Last verified: January 2011

January 25, 2011
January 26, 2011
January 2011
January 2012   (final data collection date for primary outcome measure)
Ocular surface index score [ Time Frame: 1 month ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01284439 on ClinicalTrials.gov Archive Site
Eye lid inflammation, corneal staining score, tear break up time and tear volume [ Time Frame: 1 month ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Hydroxypropylmethylcellulose 0.3% and Sodium Hyaluronate 0.18% for Ocular Surface Disease in Glaucoma
Effect of Hydroxypropylmethylcellulose 0.3% and Sodium Hyaluronate 0.18% in the Treatment of Ocular Surface Disease in Glaucoma Patients

To study effect of hydroxypropylmethylcellulose 0.3% and sodium hyaluronate 0.18% in the treatment of ocular surface disease in glaucoma patients.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Ocular Surface Disease
  • Glaucoma
  • Drug: hydroxypropylmethylcellulose
    TearA: QID to every 2 hous , 1-2 drops per each time , duration 1 month
  • Drug: sodium hyaluronate
    QID to every 2 hous, 1-2 drops per each time, duration 1 month
  • Experimental: TearA
    Intervention: Drug: hydroxypropylmethylcellulose
  • Experimental: TearB
    Intervention: Drug: sodium hyaluronate
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
120
February 2012
January 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • OSDI > or equal 20 and eye lid inflammation , meibomian gland inflammation,conjunctival injection,follicle at tarsus , positive corneal staining , tear break up time less than 8 seconds , tear volume less than 5.5 mm.

Exclusion Criteria:

  • Age below 18 yo
  • Active infectious corneal disease
  • Post penetrating keratoplasty or glaucoma drainage device
  • Known allergy to medication
  • Lactation , Pregnant
Both
18 Years and older
Yes
Contact: AssocProf Pinnita Tanthuvanit 02-4198036
Thailand
 
NCT01284439
655/2553(EC4)
No
AssocProf Pinnita Tanthuvanit, Department of Ophthalmology
Mahidol University
Not Provided
Principal Investigator: AssocProf Pinnita Tanthuvanit, MD Mahidol University
Mahidol University
January 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP